Onvitrelin ucalontide
Onvitrelin ucalontide (Phor18-LHRH (338613); EP-100) is a luteinizing hormone-releasing hormone (LHRH) receptor ligand. Onvitrelin ucalontide binds to functional LHRH receptors on cancer cells and mediates targeted cytotoxicity. Onvitrelin ucalontide reduces tumor volume, weight and the number of viable tumor cells in xenograft models. Onvitrelin ucalontide can be used for the research of breast cancer, ovarian cancer and prostate cancer.
For research use only. We do not sell to patients.
- CAS No.: 1174415-90-7
- Formula: C163H243N43O32
- Molecular Weight:3316.94
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Onvitrelin ucalontide (0.87 μM) potently inhibits the proliferation of human MDA-MB-435S.luc breast cancer cells, with an IC50 of 0.87 μM[1].
Onvitrelin ucalontide exhibits low acute hemolytic activity against human red blood cells (HA50 = 297.9 μM), resulting in an IC50/HA50 ratio of 0.003[1].
Onvitrelin ucalontide inhibits the proliferation of various human cancer cell lines, with its IC50 values ranging from 0.86 μM (MDA-MB-435S.luc) to 11.8 μM (SKOV-3)[1].
Onvitrelin ucalontide (0.0001-100 μM; 0.5-48 h) rapidly kills luteinizing hormone-releasing hormone (LHRH) receptor-positive human cancer cells (MDA-MB-435S, MCF-7, OVCAR-3, T47D, LNCaP) within 0.5-1 h, with an IC50 value as low as 0.5 μM; it exhibits delayed activity in LHRH receptor-negative cells and shows high resistance in non-cancer cell lines[1].
Onvitrelin ucalontide (2-10 μM; 5-30 minutes) specifically kills LHRH receptor-positive human MDA-MB-435S cancer cells within minutes by disrupting the plasma membrane, while exerting no effect on LHRH receptor-negative SKOV-3 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human cancer cell lines (MDA-MB-435S, MCF-7, OVCAR-3, SKOV-3, T47D, LNCaP) and non-cancerous cell lines (MCF-10A, NIH:3T3)
-
Concentration:0.0001-100 μM
-
Incubation Time:0.5-48 h
-
Result:Achieved maximal cytotoxic efficacy within 0.5-1 hour of incubation in LHRH receptor-positive cell lines: MDA-MB-435S had an IC50 of 1.2 μM at 0.5 hours and 0.6 μM at 1 hour; MCF-7 had IC50 values of 3.4-1.8 μM within 1 hour; OVCAR-3 had IC50 values of 6.7 μM at 0.5 hours decreasing to 0.5 μM by 1 hour.
Showed delayed activity in LHRH receptor-negative SKOV-3, with maximal efficacy (IC50 = 11.5 μM) achieved after 24 hours, matching the activity of the untargeted Phor18 (CLIP71).
Induced high resistance in non-cancerous cell lines, with IC50 values >10 μM.
-
Cell Line:human MDA-MB-435S and SKOV-3 cancer cells
-
Concentration:2-10 μM
-
Incubation Time:5-30 minutes
-
Result:Caused plasma membrane disintegration in LHRH receptor-positive MDA-MB-435S cells within 5 minutes at 10 μM.
Induced intracellular uptake, membrane blebbing, and vesicle formation in MDA-MB-435S cells within 30 minutes at 2 μM.
Showed no intracellular uptake, no membrane blebbing, and retained mitochondrial dye in LHRH receptor-negative SKOV-3 cells at 2 μM after 30 minutes.
In Vivo
Onvitrelin ucalontide (0.00002-1 mg/kg; intravenous injection; once weekly; for 3 consecutive weeks) reduces the weight of MDA-MB-435S breast cancer xenografts[1].
Onvitrelin ucalontide (2 mg/kg; intravenous injection; 3 doses administered over 14 days) induces tumor regression in multidrug-resistant OVCAR-3 ovarian cancer xenografts, reduces serum CA125 levels, and triggers tumor necrosis, with significant efficacy observable at doses as low as 0.2 mg/kg[1].
Onvitrelin ucalontide (0.002-2 mg/kg; intravenous injection; administered a total of 3 times within 14 days) inhibits tumor growth of aggressive PC-3 prostate cancer xenografts and prevents tumor-induced weight loss, with significant efficacy observed even at a dose as low as 0.002 mg/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nu/Nu nude mice (female, 5 weeks old)[1]
-
Dosage:0.02 mg/kg; 0.2 mg/kg; 2 mg/kg
-
Administration:i.v.; 3 total doses over 8 days
-
Result:Decreased tumor weights and total live tumor cell counts significantly compared to saline control and (KKKFAFA)3-LHRH control.
Achieved tumor weights similar to baseline at the 0.2 mg/kg dose.
Reduced tumor volumes significantly compared to baseline after 30 days post-treatment, with the smallest tumor volumes among LHRH conjugate groups.
Kept blood chemistry and complete blood count results within normal ranges, with no evidence of liver, kidney, or heart dysfunction; only a 1.5-fold elevation in potassium levels was noted.
-
Animal Model:Nu/Nu nude mice (female, 5 weeks old)[1]
-
Dosage:0.00002 mg/kg; 0.0002 mg/kg; 0.002 mg/kg; 0.02 mg/kg; 0.2 mg/kg; 1 mg/kg
-
Administration:i.v.; once per week; 3 weeks
-
Result:Reduced tumor volumes and weights significantly compared to saline controls at the 0.0002 mg/kg dose and above.
Reduced tumor volume and weight significantly compared to baseline at 0.002 mg/kg and higher doses.
Induced significant tumor necrosis at doses as low as 0.0002 mg/kg, while saline control and untargeted CLIP71 + LHRH groups had viable tumor cells.
-
Animal Model:Nu/Nu nude mice (female, 5 weeks old)[1]
-
Dosage:0.02 mg/kg; 0.2 mg/kg; 2 mg/kg
-
Administration:i.v.; 3 total doses over 14 days
-
Result:Reduced tumor volumes significantly compared to baseline at 0.2 mg/kg and 2 mg/kg.
Reduced tumor weights significantly compared to saline and untargeted CLIP71 controls at 0.2 mg/kg and 2 mg/kg, with tumor-free mice present in these dose groups.
Reduced serum CA125 levels significantly at 0.2 mg/kg and 2 mg/kg compared to saline controls.
Induced significant tumor necrosis, and reduced LHRH receptor levels in treated tumors by 1-2 score points.
-
Animal Model:Nu/Nu nude mice (male, 6 weeks old)[1]
-
Dosage:0.002 mg/kg; 0.02 mg/kg; 0.2 mg/kg; 2 mg/kg
-
Administration:i.v.; 3 total doses over 14 days
-
Result:Decreased tumor volumes during treatment at all doses, with significant reductions compared to saline and untargeted CLIP71 controls observed at 0.002 mg/kg and above.
Reduced median tumor weights at necropsy significantly compared to saline and CLIP71 controls across all treated groups.
Maintained body weight in treated mice, while control mice experienced severe weight loss (>10 g) due to tumor burden.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1174415-90-7
-
Molecular Weight 3316.94
-
Formula C163H243N43O32
-
Synonyms
Phor18-LHRH (338613); EP-100
-
Sequence
Lys-Phe-Ala-Lys-Phe-Ala-Lys-Lys-Phe-Ala-Lys-Phe-Ala-Lys-Lys-Phe-Ala-Lys-Gln-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly
-
Sequence Shortening
KFAKFAKKFAKFAKKFAKQHWSYGLRPG
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Onvitrelin ucalontide
- 1174415-90-7
- Phor18-LHRH (338613)
- EP-100
- EP100
- EP 100
- EP-100
- GnRH Receptor
- plasma membranes
- breast cancer
- MDA-MB-435S.luc breast cancer cells
- human red blood cells
- luteinizing hormone-releasing hormone (LHRH) receptor
- ovarian cancer
- xenograft models
- necrotic cell death
- cancer cells
- prostate cancer
- Inhibitor
- inhibitor
- inhibit